The word
"neoadjuvant" refers to a type of treatment that is given before the main treatment to make it more effective.
Full definition
The aim of
neoadjuvant chemotherapy is to eliminate active cancer cells — producing a complete response — before surgery.
«We found that very few women with HER2 - and hormone receptor - positive breast cancer with a PIK3CA mutation experienced a pathologic complete response after receiving
neoadjuvant therapy.
Kuang has teamed up with the Children's Specialty Center of Nevada and Nevada Imaging Centers to develop an earlier, non-invasive method for predicting success or failure
of neoadjuvant chemotherapy.
Loibl and colleagues investigated whether the presence of a PIK3CA mutation affected patients enrolled in the GeparSixto (G6) clinical trial in experiencing a pathologic complete response
after neoadjuvant therapy.
These agents may also have a future role
in neoadjuvant treatment for resectable metastatic melanoma.
However, fewer than half of women treated
with neoadjuvant chemotherapy achieve a complete response.
Participants in the G6 clinical trial
received neoadjuvant chemotherapy (paclitaxel and nonpegylated - liposomal doxorubicin) and were randomly assigned the chemotherapy carboplatin or no additional chemotherapy.
Tumor downstaging was shown in most patients receiving
neoadjuvant treatment with a low incidence of involved [circumferential resection margins (CRMs)-RSB- in the surgical specimens.
Pazopanib
Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II / III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC # 737754, IND # 118613)
«Our data suggest that early - stage HER2 - positive breast cancers treated with
neoadjuvant combination docetaxel, carboplatin, and trastuzumab with or without pertuzumab demonstrate tumor immune microenvironment phenotype changes,» the authors concluded.
Ecker BL, Paulson EC, Datta J, Jeganathan AN, Aarons C, Kelz RR, Mahmoud NN: Lymph node identification
following neoadjuvant therapy in rectal cancer: A stage - stratified analysis using the surveillance, epidemiology, and end results (SEER)- Medicare database Journal of Surgical Oncology 112 (4): 415 - 420,2015.
Addition of bevacizumab to trastuzumab -
based neoadjuvant chemotherapy in HER2 - positive inflammatory breast cancer (IBC) was associated with favorable outcome in the BEVERLY - 2 phase II trial.
Known
as neoadjuvant therapy, systemic treatment prior to surgery is often an option for some other cancers, such as breast, in early stages but was not available for melanoma patients until recently because of the lack of treatments with favorable response rates.
The analysis found that patients who
underwent neoadjuvant therapy had slightly higher 30 - day and 90 - day mortality without providing a survival advantage among patients whose cancer had spread to their lymph nodes.
Due to the development of more effective therapies, the Melanoma Moon Shot has opened two exciting
neoadjuvant clinical trials — co-led by Jennifer Wargo, M.D., and Rodabe Amaria, M.D. — and has begun enrolling patients.
The long term follow - up results suggest that new treatment strategies
incorporating neoadjuvant chemotherapy are required, because adjuvant chemotherapy does not demonstrate any significant long term benefit on overall survival or disease - free survival.»
Contrast - enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after
neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer Symposium.
«To evaluate these findings in a group with only one HER2 treatment, we are currently analyzing data from another clinical trial, the GeparQuinto clinical trial, which is a randomized, phase III clinical trial evaluating two
different neoadjuvant therapy regimens with a single anti-HER2 treatment [trastuzumab or lapatinib] for women with HER2 - positive breast cancer,» said Loibl.
Treatment given to shrink or eliminate a tumor before surgery is
called neoadjuvant therapy.
«We also need to integrate PIK3CA mutation analysis of breast tumors into routine practice so that we can ensure women receive the most
appropriate neoadjuvant therapy for their tumor type.»
A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PDL-1 Antibody) in Combination with
Neoadjuvant Anthracycline / Nab - Paclitaxel - Based Chemotherapy Compared with Placebo and Chemotherapy in Patients with Primary Invasive Triple - Negative Breast Cancer
A pilot study of
neoadjuvant paclitaxel and radiation therapy with correlative molecular studies in Stage II / III breast cancer.
Two
other neoadjuvants, doxorubicin and cyclophosphamide, also promoted metastasis by altering the tumor microenvironment.
«Biomarkers determining who will or will not completely respond to
neoadjuvant TCHP [trastuzumab, carboplatin, docetaxel, and pertuzumab] are lacking,» wrote study authors led by Jeremy Force, DO, of Duke University School of Medicine in Durham, North Carolina.
Two new studies have found that some HER2 - positive and triple - negative breast cancer patients can avoid sentinel lymph node biopsy after
neoadjuvant systemic therapy.
[58] There are few data regarding the use of radiotherapy for vulvovaginal mucosal melanoma; however, the Gynecologic Cancer InterGroup consensus recommended consideration of
neoadjuvant hypofractionated radiation in order to achieve a less radical local excision.
Chemosensitivity Predicted by BluePrint 80 - Gene Functional Subtype and MammaPrint in the
Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
Seventy - seven cases from two
neoadjuvant aromatase inhibitor clinical trials underwent next - gen sequencing (46 whole - genome, 31 exome).
Clinical Breast Cancer 2013, Final Results from Phase II Trial of
Neoadjuvant Docetaxel and Capecitabine Given Sequentially or Concurrently for HER2 - Negative Breast Cancers
A drawback of this approach is that determining
whether neoadjuvant therapy has done its job can only happen via tumor - tissue analysis following surgery.
«In an era of increasing use of minimally invasive surgery that enables administration of adjuvant therapy more reliably,» says Dr. Yendamuri, «the paradigm of
routine neoadjuvant therapy for patients with this stage of disease should be reconsidered.»
We conducted a meta - analysis in nonmetastatic breast cancer patients treated
by neoadjuvant chemotherapy (NCT) to assess the clinical validity of circulating tumor cell (CTC) detection as a prognostic marker.
Neoadjuvant T - VEC followed by surgery will be compared with surgery alone.
She is the Principle Investigator of the I - SPY TRIAL program, a
multi-site neoadjuvant clinical trial (which includes phase 2 and 3 trials) that has evolved into a model for translational research and innovation in clinical trial design.
SLNB is commonly used
following neoadjuvant therapy, but evidence has suggested that many women may not have any residual disease in the lymph nodes at this point.
Balkwill and colleagues collected pre - and post-chemotherapy biopsies and blood samples from 54 patients with advanced - stage HGSC who underwent platinum -
based neoadjuvant (given prior to surgery) chemotherapy, and from six patients who underwent surgery without prior chemotherapy.
Discussions of alternative treatment strategies, such
as neoadjuvant chemotherapy followed by surgical cytoreduction and adjuvant chemotherapy are included, together with the management of recurrent ovarian cancer, both from a surgical perspective and from a perspective of chemotherapeutic agents.
In one study, researchers included 90 patients with either HER2 - positive or triple - negative breast cancer who
underwent neoadjuvant treatment; of those, 54 patients (60 %) were cN0, and 36 (40 %) were cN1.
According to Professor Malata, «As these cases demonstrate, line - associated thrombosis will be increasingly encountered by surgeons as more patients
receive neoadjuvant chemotherapy and are managed by indwelling venous access devices.
«Notably, we were able to identify melanoma patients at high risk of both distant metastatic relapse and local recurrence, which is consistent with studies showing that ctDNA can signal micrometastatic disease
after neoadjuvant chemotherapy post surgical resection in breast cancer, and following surgery for stage II colorectal cancer.»
Following surgery, adjuvant therapy will consist of up to 12 months of atezolizumab in participants who demonstrate clinical benefit
with neoadjuvant therapy.
Previous work has shown that induction of the nuclear foci of RAD51, an HRR protein, after
neoadjuvant chemotherapy could be a measure of HRR functionality and can predict treatment response.
This study is designed to evaluate the safety and efficacy
of neoadjuvant and adjuvant atezolizumab in participants with Stage IB, II or IIIA NSCLC who are eligible for surgical resection with curative intent.
Discovery of actionable therapy targets in drug - resistant breast tumors after neoadjuvant therapy
Neoadjuvant chemotherapy, given for five to six months before surgery, is the standard treatment for some women with newly diagnosed invasive, but operable, breast cancer.
Phrases with «neoadjuvant»